Aller au contenu principal

Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes

Laboratory presentation

The national infrastructure in Health Biology IDMIT is composed of advanced laboratories allowing i) the development and validation of preclinical models (non-human primates / HNP) of infected animals, ii) tracking and / or discovery of markers molecular and / or cellular aspects of infection, inflammation, iii) study (efficacy, safety), improvement (immunogenicity, biodistribution) of new vaccines and innovative therapeutic solutions, and iv) imaging follow-up vivo transmission, dissemination of pathogens, vaccines, nano-objects, or therapeutic molecules (proteins, peptides, aptamers, microbicides ...). The IDMIT infrastructure is associated with several research and technology development teams located on the Kremlin Bicêtre hospital site, which facilitates the transition from innovative preclinical research to clinical practice. IDMIT benefits from laboratories and class 2, 3 and 3 (aerosol) laboratories allowing studies on non-human primates of many infectious pathogens (viruses, bacteria, parasites), as well as the development of preclinical models in relation with the biology threat. IDMIT notably has new technologies such as flow cytometry coupled to mass spectrometry (CyTof), and is developing a single platform in Europe for in vivo imaging involving non-human primates: optical imaging (biosponium microspie on primates) ), MRI (collaboration with MirCen), nuclear imaging (PET-CT). The presence within IDMIT of OncoDesign (Laboratoire PharmImmune) ensures professionalisation and conformity of the industry type of studies and relations, particularly towards industrial partners. Finally, IDMIT hosts a team (Axénis) from Genoway, a team specializing in the development of humanized mice for their immune system, which makes it possible to test / verify the efficacy of new drugs, vaccines or treatments.

The 20 latest publications

Title Authors Publication date Source
Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): A consensual composite score for assessing treatment effect in primary Sjögren's syndrome R. Seror, Marine Camus, Xavier Mariette 07/01/22 Annals of the Rheumatic Diseases
Modelling the response to vaccine in nonhuman primates to define SARS-CoV-2 mechanistic correlates of protection Romain Marlin, Nidhal Kahlaoui, Thibaut Naninck, Benoit Delache, Mathilde Galhaut, Nathalie Dereuddre-Bosquet, Mariangela Cavarelli, Pauline Maisonnasse, Roger Le Grand 07/01/22 eLife
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases Samuel Bitoun, Delphine Desjardins, Candie Joly, Marie Bitu, B. Ly, Juliette Pascaud, R. Seror, Roger Le Grand, X. Mariette 06/01/22 Arthritis and Rheumatology
Sjögren's disease: Risk of lymphoma and myeloma G. Nocturne 06/01/22 Revue du Rhumatisme Monographies
Management of oral and ocular dryness G. Nocturne 06/01/22 Revue du Rhumatisme Monographies
Future treatments for Sjögren's disease R. Seror, G. Nocturne, X. Mariette 06/01/22 Revue du Rhumatisme Monographies
How to follow patients with Sjögren's syndrome? Elodie Rivière, Rakiba Belkhir, G. Nocturne, X. Mariette, R. Seror 06/01/22 Revue du Rhumatisme Monographies
MDR bacterial isolates in environmental samples from Kinshasa, Democratic Republic of the Congo Saoussen Oueslati, Marianne Croue, Lara Carvahlo, Laurent Dortet, Thierry Naas 06/01/22 Journal of Antimicrobial Chemotherapy
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database R. Seror, X. Mariette 06/01/22 RMD Open
Reprogramming dysfunctional CD8<sup>+</sup> T cells to promote properties associated with natural HIV control Katia Bourdic, Christine Bourgeois, Olivier Lambotte 06/01/22 Journal of Clinical Investigation
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis Olivier Lambotte 06/01/22 Frontiers in Immunology
Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes Christine Bourgeois, Aurélie Barrail-Tran, Rogerle Grand, Delphine Desjardins, Olivier Lambotte 06/01/22 Cells
Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry Xavier Mariette, R. Seror 05/01/22 Joint Bone Spine
Use of <sup>18</sup>F FDG PET-CT to discriminate polymyalgia rheumatica and atypical spondylarthritis in clinical practice G. Nocturne 05/01/22 Joint Bone Spine
Sjögren's syndrome and other rare and complex connective tissue diseases: An intriguing liaison X. Mariette 05/01/22 Clinical and Experimental Rheumatology
The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET X. Mariette 05/01/22 Clinical and Experimental Rheumatology
Emergence of VIM-producing Enterobacter cloacae complex in France between 2015 and 2018 Cécile Emeraud, Lauraine Gauthier, Rémy A. Bonnin, Thierry Naas, Laurent Dortet 04/01/22 Journal of Antimicrobial Chemotherapy
Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice Thibaut Gelé, Olivier Lambotte, Aurélie Barrail-Tran 04/01/22 Journal of Antimicrobial Chemotherapy
Characterization of VIM-1-, NDM-1- and OXA-48-producing Citrobacter freundii in France Laura Biez, Rémy A. Bonnin, Thierry Naas, Laurent Dortet 04/01/22 Journal of Antimicrobial Chemotherapy
Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers-authors' response Mǎdǎlina Maria Muntean, Andrei Alexandru Muntean, Elodie Creton, Garance Cotellon, Saoussen Oueslati, Delphine Girlich, Rémy A. Bonnin, Thierry Naas 04/01/22 Journal of Antimicrobial Chemotherapy

Number of publications of the laboratory by scientific field (2016-2021)

Every paper can be classified in one or more scientific fields. The figure below shows the lab's number of publications in each scientific field, according to the ASJC classification (Elsevier)